Original Article

Lamotrigine, an antiepileptic drug, inhibits 5-HT$_3$ receptor currents in NCB-20 neuroblastoma cells

Ki Jung Kim$^1$, Seung Hyun Jeun$^2$, and Ki-Wug Sung$^2$*

$^1$Department of Physiology, Augusta University, Augusta, GA 30912, USA, $^2$Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea

ABSTRACT Lamotrigine is an antiepileptic drug widely used to treat epileptic seizures. Using whole-cell voltage clamp recordings in combination with a fast drug application approach, we investigated the effects of lamotrigine on 5-hydroxytryptamine (5-HT)$_3$ receptors in NCB-20 neuroblastoma cells. Co-application of lamotrigine (1–300 $\mu$M) resulted in a concentration-dependent reduction in peak amplitude of currents induced by 3 $\mu$M of 5-HT for an IC$_{50}$ value of 28.2±3.6 $\mu$M with a Hill coefficient of 1.2±0.1. These peak amplitude decreases were accompanied by the rise slope reduction. In addition, 5-HT$_3$-mediated currents evoked by 1 mM dopamine, a partial 5-HT$_3$ receptor agonist, were inhibited by lamotrigine co-application. The EC$_{50}$ of 5-HT for 5-HT$_3$ receptor currents were shifted to the right by co-application of lamotrigine without a significant change of maximal effect. Currents activated by 5-HT and lamotrigine co-application in the presence of 1 min pretreatment of lamotrigine were similar to those activated by 5-HT and lamotrigine co-application alone. Moreover, subsequent application of lamotrigine in the presence of 5-HT and 5-hydroxyindole, known to attenuate 5-HT$_3$ receptor desensitization, inhibited 5-HT$_3$ receptor currents in a concentration-dependent manner. The deactivation of 5-HT$_3$ receptor was delayed by washing with an external solution containing lamotrigine. Lamotrigine accelerated the desensitization process of 5-HT$_3$ receptors. There was no voltage-dependency in the inhibitory effects of lamotrigine on the 5-HT$_3$ receptor currents. These results indicate that lamotrigine inhibits 5-HT$_3$-activated currents in a competitive manner by binding to the open state of the channels and blocking channel activation or accelerating receptor desensitization.

INTRODUCTION

5-Hydroxytryptamine (5-HT)$_3$ receptors are the only ligand-gated ion channels (LGIC) among the subfamilies of 5-HT receptors. Based on structural and functional properties, 5-HT$_3$ receptors are members of the Cys-loop family of LGIC, which includes glycine, GABAA and nicotinic acetylcholine (nACh) receptors [1-4]. These receptors are widely distributed in the central and peripheral nervous systems [5-7]. Given their expression at both pre- and post-synaptic terminals, their activation modulates the release of various neurotransmitters such as dopamine, cholecystokinin, GABA, substance P and acetylcholine. Moreover, antagonism of 5-HT$_3$ receptors results in antiemetic [8], anxiolytic [9], and antipsychotic effects [10] suggesting an important role of this receptor in neuronal function. 5-HT$_3$ receptors are remarkably sensitive to a number of pharmacological agents, thus constituting important therapeutic target for the treatment of neuronal disorders such as...
voltage-gated Na+ channels, the antiepileptic effects can be ascribed to the inhibition of voltage-gated Na+ channels, resulting in blockade of the release of excitatory amino acid transmitters [15]. It has been also reported that lamotrigine acts as an open channel blocker for the nACh receptor [16,17], and alters 5-HT release in a rat brain [18,19]. Moreover, lamotrigine modulates 5-HT uptake in rats [20]. Altogether these results suggest lamotrigine as a potential agent in the treatment of neuropsychiatric disorders such as schizophrenia, bipolar disorder, and anxiety disorders [21].

A study using a binding assay method reported that lamotrigine weakly binds to 5-HT₃ receptors [22]. However, no studies have addressed its role on 5-HT₃ receptors using electrophysiological techniques to better assess the functional outcomes of its binding to the receptor. Thus, using the whole-cell patch clamp in combination with a fast drug application approach, we tested the effects of lamotrigine on 5-HT₃ receptor function. Based on our results we suggest an additional pharmacological mechanism with therapeutic potential for neuropsychiatric disorders associated with 5-HT₃ receptor dysfunction.

**METHODS**

**Cell culture**

NCB-20 neuroblastoma cells (kindly provided by Dr. Lovinger, National Institute on Alcohol Abuse and Alcoholism, USA) were maintained under conditions previously described conditions [23]. Frozen cell stocks were maintained in liquid nitrogen, and thawed as needed. Cells were maintained in a medium containing 90% Dulbecco’s modified Eagle’s medium, 10% fetal bovine serum, and 1% hygromycin aminopterin thymidine supplement, and were cultured in an incubator containing 5% CO₂ at 37°C. Cells were seeded on 35 mm culture dishes at least 24 h prior to electrophysiological experiments.

**Electrophysiology**

For whole-cell patch-clamp recordings, NCB-20 cells were plated on cover glasses (12 mm diameter; Fisher Scientific, Pittsburgh, PA, USA) and transferred to the recording chamber (RC-13, Warner Instruments, Hamden, CT, USA) mounted on the stage of an inverted microscope (IX70, Olympus, Tokyo, Japan) at room temperature (21-24°C), as previously described [23]. Cells were continuously perfused with an extracellular solution containing (in mM) 150 NaCl, 2.5 KCl, 2.5 CaCl₂, 10 N-(2-hydroxyethyl)piperazine-N’-2-ethansulfonic acid (HEPES), and 10 D-glucose (pH adjusted to 7.4 with NaOH and osmolality adjusted to 340 mOsm/kg with sucrose) at a rate of 2-3 ml/min through the theta glass micropipette (see below in Drug preparation and application). Patch pipettes were pulled from borosilicate glass capillaries (IBI50-4, World Precision Instruments, Sarasota, FL, USA) using a programmable horizontal micropipette puller (P-97, Sutter Instrument, Novato, CA, USA). Pipette tips had resistances of 2.0-3.0 MΩ when filled with an internal solution containing (in mM) 140 CsCl, 2 MgCl₂, 5 ethylene glycol bis(2-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA), 10 HEPES, (pH adjusted to 7.2 with CsOH, osmolality adjusted to 310 mOsm/kg with sucrose). Whole-cell currents were recorded using an Axopatch 200B amplifier and pClamp 9.2 software (Molecular Devices, Sunnyvale, CA, USA). All experiments were carried out at a holding potential of –50 mV unless otherwise stated. The current signals were filtered at 2 kHz, digitized at 10 kHz, and saved on a PC using DigiData 1322 and pClamp 9.2 software (Molecular Devices). The liquid junction potentials between the pipette and bath solutions were 3-5 mV, and were zeroed before a gigaohm seal was formed. Capacitive currents were compensated with analog compensation, but leak subtraction was not used in this study.

After achieving a whole-cell configuration, a variable amount of current run-down was typically observed for several minutes. To minimize run-down condition, we waited at least 10 min after getting whole-cell configuration, and drug applications were carried out at 2 min intervals. At the end of the experiments, 5-HT-induced currents that decreased more than 20% in comparison with the first current were excluded from the data analysis.

**Drug preparation and application**

A fast drug application technique was used to induce the 5-HT₃ receptor currents and to evaluate the drug effects as previously described [23]. After establishing a whole-cell configuration, cells were lifted up and positioned in front of one side of theta glass micropipette, which was pulled from the theta glass micropipette (Clark Borosilicate Theta, Warner Instruments; 2 mm outer diameter, 1.4 mm inner diameter, 0.2 mm septum thickness) to an outer diameter of ~300 μm, and continuously perfused with an extracellular solution. The extracellular solution, which contained agonists with or without drug, flowed through a different side of the theta glass micropipette. Solutions were rapidly switched around the cell by the linear movement of theta glass micropipette mounted on a piezoelectric translator (P-601 PiezoMove Z, Piezomechnik, Germany).
Lamotrigine blocks 5-HT$_3$ receptor opening

Actuator, Physik Instrumente, Karlsruhe, Germany), which displaced the theta glass micropipette laterally so that the cell could be exposed for a defined period of time to the drug-containing solution, and then rapidly returned to the drug-free extracellular solution. The piezoelectric translator was controlled by a Piezo Servo Controller (E-625, Physik Instrumente) and triggered by pClamp 9.2 software (Molecular Devices). The rate of solution exchange was usually 24.4±5.3 msec (n=11) in the open pipette tip configuration [24]. Solution flow was driven by gravity from reservoirs placed above the preparation, and the application of solutions was controlled by a perfusion valve control system (VC-8, Warner Instruments, Hamden, CT, USA).

The agonist and other drugs were diluted in the extracellular solution from stock solutions in distilled water. Lamotrigine was dissolved in dimethyl sulfoxide (DMSO, 30 mM stock) and further diluted in the extracellular solution with or without the agonist. Lamotrigine was purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). All other chemicals were purchased from Sigma Chemicals (St. Louis, MO, USA). Cell culture reagents were obtained from Gibco BRL (Rockville, MD, USA). Solutions were freshly prepared prior to each experiment.

Data analysis and statistics

Peak amplitudes of currents were measured using Clampfit 9.2 software (Molecular Devices), by determining the differences in currents before and during agonist application. The rise slopes of current were also analyzed to evaluate 5-HT$_3$ receptor activation using the built-in statistical tools in Clampfit 9.2 software. Since peak amplitudes of the 5-HT$_3$ receptor currents induced by agonist application varied among cells, data were normalized to the maximal values in each cell. Receptor desensitization was measured as the decay in the 5-HT$_3$ receptor currents in the continuous presence of the agonist (10 sec). Receptor deactivation was measured as the current decay in response after brief application of the agonist for 10 msec. Both current decays by desensitization and deactivation were fitted to a double exponential function, then analyzed and compared the time constants for fast and slow component of current decays.

Concentration–response data were fitted to a sigmoid curve, as calculated by the four-parameter logistic equation using Prism 4.0 software (GraphPad Software, San Diego, CA, USA). For the EC$_{50}$ of 5-HT:

$$Y = \text{bottom} + \frac{\text{top} - \text{bottom}}{1 + 10^{((\log EC_{50} - X)/\text{Hillslope})}}$$

where the bottom is the minimal response, top is the maximal response by 5-HT, X is the logarithm of concentrations of tested agonist and EC$_{50}$ is the concentration of 5-HT that gives a response half way between bottom and top. For the IC$_{50}$ of lamotrigine:

$$Y = \text{bottom} + \frac{\text{top} - \text{bottom}}{1 + 10^{((\log IC_{50} - X)/\text{Hillslope})}}$$

where the bottom is the maximally inhibited response by lamotrigine, top is the maximal response by 5-HT alone, X is the logarithm of concentrations of lamotrigine and IC$_{50}$ is the concentration of lamotrigine resulting in a response half way between bottom and top.

The averaged values were expressed as mean±S.E.M. Statistical significance was determined by the Student’s t-test. p<0.05 was considered to be statistically significance.

RESULTS

Inhibitory effects of lamotrigine on 5-HT$_3$ receptor activation

To determine the direct effects of lamotrigine on 5-HT$_3$ receptor currents, we studied the concentration-dependent responses of lamotrigine (1~300 μM) on the currents activated by 3 μM of 5-HT, near EC$_{50}$ of 5-HT$_3$ receptor currents in our previous report [23]. Application of lamotrigine (300 μM) alone did not induce any current (data not shown). Co-application of lamotrigine reduced the peak amplitudes of 3 μM 5-HT-induced currents in a concentration-dependent manner (Fig. 1A). The IC$_{50}$ value of lamotrigine for the peak amplitude reduction was 28.2±3.6 μM with a Hill coefficient of 1.2±0.1 (Fig. 1C, n=8). In addition to reducing the peak amplitude, lamotrigine also decreased the rise slope of 5-HT$_3$ receptor currents, an indicator of activation of the 5-HT$_3$ receptor [25], induced by 3 μM of 5-HT. The IC$_{50}$ value for the rise slope decreases by lamotrigine was 21.7±4.9 μM with a Hill coefficient of 1.4±0.2 (Fig. 1D, n=8).

To further investigate the effects of lamotrigine on 5-HT$_3$ receptor activation, we used dopamine (DA), a partial 5-HT$_3$ receptor agonist [26]. Currents activated by 1 mM of DA were characterized by a slow rise time, smaller peak amplitude (compared to that of a full agonist, i.e., 5-HT) and, either no decay or a small slow decay during DA application for 5 sec (Fig. 1B). It has been also reported that DA-induced currents in NCB-20 cells were completely blocked by zacopride, a potential and highly selective 5-HT$_3$ receptor antagonist [26]. These results suggest that DA directly activates the 5-HT$_3$ receptors without strong desensitization. Therefore, it is possible to clarify further effects of lamotrigine on the activation or the open process of 5-HT$_3$ receptors [26]. We then studied the effect of lamotrigine (1~300 μM) on 1 mM DA-induced currents (Fig. 1B). Co-application of lamotrigine with DA reduced the peak amplitude in a concentration-dependent manner. The IC$_{50}$ value of the peak amplitude was 18.2±6.7 μM with a Hill coefficient of 1.3±0.6 (Fig. 1E, n=6). The IC$_{50}$ values of lamotrigine on the inhibition of peak amplitude were similar between the 5-HT$_3$ receptor currents activated by a full agonist, 5-HT and a partial agonist, DA. These
results suggest that the inhibitory action of lamotrigine on 5-HT₃ receptors resulted from the blockade of the channel activation process.

Fig. 2A shows the representative 5-HT₃ receptor currents evoked by 1, 3, 10, 30 μM of 5-HT with or without lamotrigine co-application (30 μM, near IC₅₀ based on other experiments mentioned in this study) to study whether lamotrigine inhibits the 5-HT₃ receptor competitive manner. Co-application of lamotrigine attenuated the currents activated by 0.1~30 μM of 5-HT (Fig. 2B). EC₅₀ value of peak currents induced by co-application of 5-HT and 30 μM of lamotrigine was 4.2±0.3 μM with Hill coefficient of 2.3±0.1 (n=9). Co-application of 30 μM of lamotrigine increased the EC₅₀ (p<0.05, unpaired t-test) however, the Hill coefficient change was not statistically significant (p=0.5698). The maximum of peak currents, reached at 30 μM of 5-HT, were not significantly different between those with and without 30 μM of lamotrigine (96.1±4.0% and 104.1±1.9% of 10 μM 5-HT response, respectively; p=0.0843, unpaired t-test). These results suggest that lamotrigine inhibits 5-HT₃ receptor activation in a competitive manner.

In order to determine whether the lamotrigine also affects the closed state of the 5-HT₃ receptor, cells were pretreated with 30 μM lamotrigine for 1 min prior to the co-application of 3 μM 5-HT with lamotrigine, and compared to 3 μM 5-HT and 30 μM lamotrigine co-applications without pretreatment of lamotrigine (Fig. 3A). Following a 1 min pretreatment, no differences were observed in the inhibition of peak amplitudes by the co-application of 5-HT and lamotrigine after 1 min pretreatment (50.4±1.2% of 5-HT only) when compared to the co-application without pretreatment of lamotrigine (50.6±1.8%) (Fig. 3B, n=8, p=0.8586, paired t-test). These results indicate that lamotrigine is unlikely to bind to the closed state of the receptor but readily binds to the open or active state.

To address, in detail, the effects of lamotrigine on the 5-HT₃ receptor open state, we next applied lamotrigine (1~300 μM) on 5-HT (10 μM) and 5-hydroxyindole (5-HI, 1 mM)-induced currents (Fig. 4). Our previous report showed that 1 mM 5-HI blocked the desensitization of 10 μM 5-HT-induced currents without changes in peak amplitude [24], which remained 5-HT₃ receptor to open or activated states. The currents activated by 10 μM 5-HT with 1 mM 5-HI were decreased following subsequent application of lamotrigine in a concentration-dependent manner. A concentration of 300 μM lamotrigine was sufficient to cause a complete blockade of the currents (Fig. 4A). The IC₅₀ value of lamotrigine for the inhibition of open state of the 5-HT₃ receptor was 36.6±2.2 μM with a Hill coefficient of 0.5±0.1 (Fig. 4B, n=9).

Effects of lamotrigine on 5-HT₃ receptor deactivation and desensitization

To examine if lamotrigine could alter 5-HT₃ receptor deactivation, exposure to the external solution in the presence
or absence of 30 μM lamotrigine, followed immediately after a brief application of 5-HT for 10 msec (Fig. 5A). A high 5-HT concentration (10 μM) was used to induce more profound channel deactivation following activation. The decay of 5-HT<sub>3</sub> receptor currents induced by application of 10 μM 5-HT for 10 msec were fitted to a double exponential function and analyzed the fast and slow component of time constants for current decay. As shown in Fig. 5B, the presence of lamotrigine (30 μM) after 10 msec application of 5-HT slowed the current decay. The slow decay time constant was increased from 1640.6±74.3 to
1961.9±100.9 msec (n=8, p<0.05, paired t-test). However, the time constant for fast current decay was not changed by lamotrigine (322.2±36.7 msec for 5-HT alone and 312.1±47.3 msec for lamotrigine washing, n=8, p=0.6343, paired t-test). These results suggest that lamotrigine attenuates the deactivation of 5-HT₃ receptors after channel opening.
The effect of lamotrigine on the 5-HT₃ receptor desensitization was also studied using a long application of 5-HT to induce the receptor desensitization with or without lamotrigine, then analyzed current decay time constants. Fig. 5C shows the superimposed current traces induced by 10 μM of 5-HT (10 sec) with or without 30 μM of lamotrigine. The current decay during application of 5-HT was fitted to a double exponential function, and accelerated by co-application of lamotrigine. As shown in Fig. 5D, the time constant for fast current decays were not significantly changed by lamotrigine (455.2±28.2 msec for 5-HT alone and 482.1±40.6 msec for lamotrigine co-application, n=8, p=0.415, paired t-test), however the time constant for the slow component of current decays were decreased from 4640.0±632.8 to 3732.0±454.8 msec (n=8, p<0.01, paired t-test). These results suggest that lamotrigine accelerates the 5-HT₃ receptor desensitization after receptor activation.

Voltage-independence of lamotrigine on 5-HT₃ receptor inhibition

To evaluate the voltage-dependence of lamotrigine-induced inhibitory effects, 5-HT₃ receptor currents were recorded in the presence or absence of lamotrigine at different holding potentials (–50~+30 mV). Lamotrigine decreased 5-HT-induced currents over the entire voltage range tested (Fig. 6A). Fig. 6B shows a plot of 5-HT₃ receptor currents, induced by 3 μM of 5-HT and normalized to the currents at –50 mV of holding potential, against tested holding potentials in the presence or absence of lamotrigine (30 μM). Current-voltage relationships for peak amplitudes were almost linear, and calculated reversal potentials by linear regression were 3.4±0.5 mV and 3.5±0.7 mV in the absence and presence of lamotrigine, respectively. The reversal potential of 5-HT-induced currents was not changed by the co-application of lamotrigine (n=7, p=0.8076, paired t-test). The fractional blockade was calculated at the different holding potentials, and inhibitory effects of lamotrigine over all tested membrane potential ranges were similar in the presence of lamotrigine (Fig. 6C). These results indicate that the inhibitory actions of lamotrigine did not depend on voltage.

DISCUSSION

In the present study, we investigated the inhibitory actions of lamotrigine, an antiepileptic drug, on 5-HT₃ receptors naturally expressed in NCB-20 neuroblastoma cells. Our results suggest that lamotrigine inhibits 5-HT₃ receptor function predominantly by blocking channel opening, as substantiated by a lamotrigine-induced lowering of the peak amplitude accompanied with the reduction in the rise slope of currents, an indicator of activation of 5-HT₃ receptor [25], in concentration-dependent manner. Similar effects were obtained in DA experiments, under conditions were the channels are more likely to be in their open states without profound desensitization [26]. Thus, we suggest lamotrigine-induced inhibition of 5-HT₃ receptor function occurs during the receptor activation phase, i.e., channel open. This observation is supported by our finding that the pretreatment of lamotrigine for 1 min did not exert a significant effect on the 5-HT₃ receptor currents induced by co-application of 5-HT and lamotrigine, which suggesting the possibility of lamotrigine binding to closed state of 5-HT₃ receptors, and thereby block subsequent opening could be excluded. To further investigate the interaction of lamotrigine with the 5-HT₃ receptor during the open state of the receptor, experiments were conducted in the presence of 5-HI. In a previous report we showed that 1 mM 5-HI efficiently slowed 5-HT₃ receptor desensitization generated by 10 μM 5-HT without any effect on peak amplitudes [24]. Application of lamotrigine in the presence of 5-HT and 5-HI inhibited 5-HT₃ receptor currents in a concentration-dependent manner. These results also suggest that lamotrigine preferentially works in the open states of 5-HT₃ receptors and then inhibits the currents. In a series of these experiments, the calculated IC₅₀ values of lamotrigine on 5-HT₃ receptor currents showed little variance in a range of 20~40 μM. These results suggest that lamotrigine exerts 5-HT₃ receptor
Lamotrigine was also observed to alter the deactivation and desensitization properties of 5-HT3 receptor channels, i.e. the slow time constants for current decays by the 5-HT3 receptor. Deactivation were attenuated and the slow time constants for current decays by the 5-HT3 receptor were accelerated by lamotrigine. As with many ligand-gated ion channels, channel deactivation and desensitization are correlated with the opening of the ion channels--for example, if more channels are activated, they will be more strongly deactivated and desensitized. In other words, if the degree of channel activation is increased, the rate of deactivation and desensitization is accelerated in an agonist concentration-dependent manner [25,27]. Therefore, the attenuation of 5-HT3 receptor deactivation and the acceleration of receptor desensitization by lamotrigine in our experiment could be explained by secondary changes following inhibition of channel opening. However, a direct effect of lamotrigine on the deactivation and desensitization steps of the 5-HT3 receptor could not be ruled out, because it has been reported that some drugs modulate 5-HT3 receptor function directly acting on the receptor deactivation or desensitization process [28,29]. Thus, further studies elucidating the effect of lamotrigine on receptor deactivation and desensitization are needed.

In our study, lamotrigine caused an inhibition in peak amplitudes in a voltage-independent manner. The voltage-dependency of a drug effect is considered as evidence for a mechanism of open channel blocking in the voltage-gated ion channels as well as the ligand-gated ion channels, including 5-HT3 receptors. For example, diltiazem acted as an open channel blocker on 5-HT3 receptors and caused a voltage dependency [30]. However, lamotrigine is a basic drug with pKa5.7 [31] and predominates in its uncharged form at physiological pH. Therefore, it should be considered that if the major mechanism of action of lamotrigine on 5-HT3 receptors is thought to involve the uncharged form of the drug, lamotrigine should block the currents in a voltage independent manner, even though it works as an open channel blocker on the 5-HT3 receptors. These results suggest that lamotrigine could bind to the 5-HT3 receptor voltage independently during activation and inhibits ion channel opening. This interpretation should be tested further, because our findings that the peak amplitude decreases accompanied with rise slope reduction (Fig. 1), no significant effects of 1 min pretreatment of lamotrigine (Fig. 3), and inhibition of open states of 5-HT3 receptor by lamotrigine (Fig. 4), are all suggesting the open channel blocking mechanism of lamotrigine action. It has been reported that fluoxetine inhibited the 5-HT3 receptor function with open channel blocking mechanism, but it showed voltage independency in its inhibition [32]. Therefore, lamotrigine could act as an open channel blocker with voltage-independency. 5-HT3 receptors modulate the release of various neurotransmitters such as dopamine, GABA and glutamate in the central nervous system [33-35], and are implicated in complex neuronal functions [1,8,36]. Reports for the antagonist of 5-HT3 receptors indicate these receptors play important roles in neuropsychotropic actions such as schizophrenia [37,38]. In addition, lamotrigine blocks voltage-gated Na+ channel, which is believed to mediate its antiepileptic activity [39], resulting in blockade of the release of excitatory neurotransmitters [40]. Furthermore, other reports suggest that lamotrigine has a potential role in neuropsychiatric disorders [22,41]. Taken together with these reports, our results suggest that the 5-HT3 receptor blocking by lamotrigine could be a potential mechanism of action in the clinical use of this drug to treat psychiatric and neurologic disorders.

In summary, we showed that lamotrigine inhibited 5-HT3 receptor activation and 5-HT3 receptor-induced currents. Lamotrigine decreased the amplitudes of 5-HT3 receptor-mediated currents during the activation phase of the channel with changes in channel deactivation and desensitization properties. Therefore, lamotrigine blocks 5-HT3 receptor-mediated currents by weakly binding to the open state of the receptors. Taken together, these results suggest that lamotrigine might contribute as a therapeutic agent for psychiatric and neurologic disorders, acting on the 5-HT3 receptors.

ACKNOWLEDGEMENTS

We thank Dr. Lovinger (NIAAA, USA) for providing us with NCB-20 cells, and Prof. Hahn (The Catholic University of Korea) and Dr. Filosa (Augusta University, USA) for helpful comments on the preparation of this manuscript. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (NRF-2014R1A1A2056820).

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083-1152.
2. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71:533-554.
3. Thompson AJ, Lummis SC. The 5-HT3, receptor as a therapeutic target. Expert Opin Ther Targets. 2007;11:527-540.
4. Walstab J, Rappold G, Niesler B. 5-HT3(3) receptors: role in disease and target of drugs. Pharmacol Ther. 2010;128:146-169.
5. Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT, recep-
Lamotrigine blocks 5-HT<sub>3</sub> receptor opening

10. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. *Neuropsychopharmacology*. 1995;13:177-213.

11. Wada Y, Shiraishi J, Nakamura M, Koshino Y. Effects of the 5-HT<sub>3</sub> receptor agonist 1-(m-chlorophenyl)-biguanide in the rat kindling model of epilepsy. *Brain Res.* 1997;759:313-316.

12. Nichols RA, Mollard P. Direct observation of serotonin 5-HT<sub>3</sub> receptor-induced increases in calcium levels in individual brain nerve terminals. *J Neurochem.* 1996;67:581-592.

13. Michal K, Zeller F, Langer R, Nekarda H, Kruger D, Dover TJ, Brady CA, Barnes NM, Schemann M. Serotonin excites neurons in the human submucous plexus via 5-HT<sub>3</sub> receptors. *Gastroenterology*. 2005;128:1317-1326.

14. Bioler M, Johannessen SI, Kupferberg JJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). *Epilepsy Res.* 2007;73:31-52.

15. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. *Epilepsia*. 1999;40:1471-1483.

16. Vallés AS, Garbus I, Barrantes FJ. Lamotrigine is an open-channel blocker of the nicotinic acetylcholine receptor. *Neuroreport*. 2007;18:45-50.

17. Zheng C, Yang K, Liu Q, Wang MY, Shen J, Vallés AS, Lukas RJ, Barrantes FJ, Wu J. The anticonvulsive drug lamotrigine blocks neuronal [alpha]4[beta]2 nicotinic acetylcholine receptors. *J Pharmacol Exp Ther.* 2010;335:401-408.

18. Ahmad S, Fowler LJ, Whitton PS. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. *Epilepsy Res.* 2005;63:141-149.

19. Ahmad S, Fowler LJ, Whitton PS. Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. *Naunyn Schmiedebergs Arch Pharmacol.* 2005;371:1-8.

20. Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. *Eur J Pharmacol.* 1998;358:19-24.

21. Reid JG, Gitlin MJ, Alshuler LL. Lamotrigine in psychiatric disorders. *J Clin Psychiatry*. 2013;74:675-684.

22. Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia. *Psychopharmacology (Berl).* 2005;181:415-436.

23. Li QZ, Cho HS, Jeon SH, Kim KJ, Choi SJ, Sung KW. Effects of grape seed proanthocyanidin on 5-hydroxytryptamine<sub>3</sub> receptors in N20 neuroblastoma cells. *Biof Rev. Pharmacol.* 2011;34:1109-1115.

24. Yang HS, Kim SY, Choi SJ, Kim KJ, Kim ON, Lee SB, Sung KW. Effect of 5-hydroxyindole on ethanol potentiation of 5-hydroxytryptamine (5-HT<sub>3</sub>), receptor-activated ion current in N20 neuroblastoma cells. *Neurosci Lett.* 2003;338:72-76.

25. Zhou Q, Verdoorn TA, Lovinger DM. Alcohol potentiates the function of 5-HT<sub>3</sub> receptor-channels on N20 neuroblastoma cells by favouring and stabilizing the open channel state. *J Physiol.* 1998;507:335-352.

26. Lovinger DM, Sung KW, Zhou Q. Ethanol and trichloroethanol alter gating of 5-HT<sub>3</sub> receptor-channels in N20 neuroblastoma cells. *Neuropharmacology*. 2000;39:561-570.

27. Jones MV, Westbrook GL. Desensitized states prolong GABA<sub>B</sub> channel responses to brief agonist pulses. *Neuron*. 1995;15:181-191.

28. Neijt HC, Plomp JJ, Vrijverberg HP. Kinetics of the membrane current mediated by serotonin 5-HT<sub>3</sub> receptors in cultured mouse neuroblastoma cells. *J Physiol.* 1989;411:257-269.

29. van Hoof JA, van der Haar E, Vrijverberg HP. AllostERIC potentiation of the 5-HT<sub>3</sub> receptor-mediated ion current in NIE-115 neuroblastoma cells by 5-hydroxyindole and analogues. *Neuropharmacology*. 1997;36:649-653.

30. Gunthorpe MJ, Lummis SC. Diltiazem causes open channel block of recombint 5-HT<sub>3</sub> receptors. *J Physiol.* 1999;519:713-722.

31. Maryadale JO, Patricia EH, Peter HD, Kristin JR. The merck index. 15th ed. Cambridge: The Royal Society of Chemistry; 2013. 5400 p.

32. Choi JS, Choi BH, Ahn HS, Kim MJ, Rhie DJ, Yoon SH, Min DS, Jo YH, Kim MS, Sung KW, Hahn SJ. Mechanism of block by fluoxetine of 5-hydroxytryptamine<sub>3</sub> (5-HT<sub>3</sub>)-mediated currents in N20 neuroblastoma cells. *Biochem Pharmacol.* 2003;66:2125-2132.

33. Funahashi M, Mito Y, Matsuo R. Activation of presynaptic 5-HT<sub>3</sub> receptors facilitates glutamatergic synaptic inputs to area postrema neurons in rat brain slices. *Methods Find Exp Clin Pharmacol.* 2004;26:615-622.

34. Liu W, Thielen RJ, McBride WJ. Effects of repeated daily treatments with a 5-HT<sub>3</sub> receptor antagonist on dopamine neurotransmission and functional activity of 5-HT<sub>3</sub> receptors within the nucleus accumbens of Wistar rats. *Pharmacol Biochem Behav.* 2006;84:370-377.

35. Turner TJ, Mokler DJ, Luebke JI. Calcium influx through presynaptic 5-HT<sub>3</sub>-receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studies. *Neuroscience*. 2004;129:703-718.

36. Lee S, Hjerling-Leffler J, Zagha E, Fishell G, Rudy B. The largest group of superficial neocortical GABAergic interneurons express ionotropic serotonin receptors. *J Neurosci.* 2010;30:16796-16808.

37. Thompson AJ, Sullivan NL, Lummis SC. Characterization of 5-HT<sub>3</sub> receptor mutations identified in schizophrenic patients. *J Mol Neurosci.* 2006;30:273-281.

38. Thompson AJ, Lummis SC. 5-HT<sub>3</sub> receptors. *Curr Pharm Des.* 2006;12:3615-3630.

39. Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIIA Na<sup>+</sup> channels and with native Na<sup>+</sup> channels in rat hippocampal neurons. *Pflugers Arch.* 1995;430:437-446.

40. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. *Epilepsia.* 2008;49:888-897.

41. Mirza NR, Bright JL, Stanhope KJ, Wyatt A, Harrington NR. Lamotrigine has an axiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? *Psychopharmacology (Berl).* 2005;180:159-168.

www.kjpp.net

Korean J Physiol Pharmacol 2017;21(2):169-177